- ILMN -1.43%
Illumina, Inc. (NASDAQ:ILMN) Q1 2024 Earnings Call Transcript
Yahoo Finance · 3 weeks ago
Search results
- 105.85Add to watchlist-1.54 (-1.43%)At close: Thu. May 23, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Pre-Market Time
- Open106.69High107.36Low104.78
- Mkt Cap16.86BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close107.3952 Wk. Low89.0052 Wk. High213.12
What analysts are sayingTop storiesRelated stocks
A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. We are dedicated to improving human health by unlocking the power of the genome.
At Illumina, our core values stem from innovation, discovery, and collaboration. As an executive team, we strive to deliver leading genomic technologies that enable boundless research discovery and pioneering personalized health.
Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
Jan 10, 2022 · Illumina delivered a strong finish to 2021, with preliminary consolidated fourth quarter revenue of approximately $1.190 billion, up 25% year-over-year. This record revenue for the quarter reflected records across both instruments and consumables.
View a complete list of Illumina sequencing and microarray products. Filter by system compatibility and other key features to narrow the list.
Aug 18, 2021 · SAN DIEGO, /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
Get the latest Illumina Inc (ILMN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
